Literature DB >> 18329581

Antifungal susceptibility testing of micafungin against Candida glabrata isolates.

Erica R Oliveira1, Annette Fothergill, William R Kirkpatrick, Thomas F Patterson, Spencer W Redding.   

Abstract

OBJECTIVE: Antifungal susceptibility of micafungin against isolates of C. glabrata was performed to evaluate the hypothesis that micafungin may be a suitable alternative in treating those patients whose infections are from C. glabrata and have developed resistance to fluconazole. STUDY
DESIGN: A total of 119 clinical isolates were obtained from the oral cavity of 22 patients with oropharyngeal candidiasis or oral colonization with C. glabrata. All strains evaluated were from patients who had either HIV infection or were receiving radiation therapy for head and neck cancer. Inocula were prepared using Clinical Laboratory and Standards Institute (CLSI) M27-A2 guidelines. The plates were incubated at 35 degrees C and the minimum inhibitory concentrations (MICs) were determined at 24 and 48 hours.
RESULTS: Micafungin exhibited good in vitro activity against most isolates, including those showing marked resistance to fluconazole.
CONCLUSION: Micafungin has excellent antifungal effects in vitro against C. glabrata isolates and appears to be a good treatment option even against those isolates resistant to fluconazole. A clinical trial should be performed to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18329581     DOI: 10.1016/j.tripleo.2007.12.003

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod        ISSN: 1079-2104


  2 in total

1.  [Candida glabrata : pathogenicity and therapy update].

Authors:  H-J Tietz
Journal:  Hautarzt       Date:  2012-11       Impact factor: 0.751

Review 2.  Vulvar pruritus-Causes, Diagnosis and Therapeutic Approach.

Authors:  Linn Woelber; Katharina Prieske; Werner Mendling; Barbara Schmalfeldt; Hans-Jürgen Tietz; Anna Jaeger
Journal:  Dtsch Arztebl Int       Date:  2020-02-21       Impact factor: 5.594

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.